Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Radiochemical Supplies Enhanced
by Marc S. Reisch
June 7, 2010
| A version of this story appeared in
Volume 88, Issue 23
Lantheus Medical Imaging has received U.S. approvals to use molybdenum-99 from the Nuclear Research Institute in Rez, Czech Republic, to produce medical isotopes. Mo-99, used to generate technetium-99m for imaging procedures, has been scarce while nuclear reactors in Canada and the Netherlands undergo repairs. Separately, PerkinElmer says it is the first firm to offer current Good Manufacturing Practice-compliant lutetium-177 nuclide. The new product, which can be used in the development of various cancer treatments, is the result of an agreement between PerkinElmer and the University of Missouri Research Reactor.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter